17
Jun
2021

Versant, RA Bet $47M on LENZ Therapeutics to Restore Near Vision in Middle Age

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Belharra Gets $130M from Versant, Genentech For Chemoproteomic Discovery
Red Tree Debuts With $272M, Zeroing In On West Coast Startups
Versant-backed Cimeio Gets $50M for Shielded Stem Cell Therapies
Versant, OrbiMed Invest $50M in Startup Inserting Genes in the Liver